Incorporating newer agents in the treatment of acute myeloid leukemia
- 1 November 2018
- journal article
- review article
- Published by Elsevier in Leukemia Research
- Vol. 74, 113-120
Abstract
No abstract availableKeywords
This publication has 45 references indexed in Scilit:
- IDH1 and IDH2 Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B StudyJournal of Clinical Oncology, 2010
- In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacyLeukemia Research, 2009
- FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplicationsBlood, 2008
- FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemiaBlood, 2007
- A comparison of low‐dose cytarabine and hydroxyurea with or without all‐trans retinoic acid for acute myeloid leukemia and high‐risk myelodysplastic syndrome in patients not considered fit for intensive treatmentCancer, 2007
- High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa groupLeukemia, 2006
- Adverse Prognostic Significance of KIT Mutations in Adult Acute Myeloid Leukemia With inv(16) and t(8;21): A Cancer and Leukemia Group B StudyJournal of Clinical Oncology, 2006
- Prognostic Factors and Outcome of Core Binding Factor Acute Myeloid Leukemia Patients With t(8;21) Differ From Those of Patients With inv(16): A Cancer and Leukemia Group B StudyJournal of Clinical Oncology, 2005
- Individual Patient Data–Based Meta-Analysis of Patients Aged 16 to 60 Years With Core Binding Factor Acute Myeloid Leukemia: A Survey of the German Acute Myeloid Leukemia IntergroupJournal of Clinical Oncology, 2004
- Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin)Leukemia, 2002